Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (41-50 of 372) with videos related to

Pageof 38
Sort By:
Leukemia & Lymphoma|August 10, 2017
Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitorsEmilie Cayssials, Florence Tartarin, Joëlle Guilhot, et al.
Leukemia Research|April 28, 2009
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemiaStéphanie Poulain, Marjan Ertault, Xavier Leleu, et al.
Cancer Immunology, Immunotherapy : CII|September 4, 2010
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitorsCéline Berthon, Virginie Driss, Jizhong Liu, et al.
Cancer Treatment and Research|October 4, 2016
Treatment of Newly Diagnosed Elderly Multiple MyelomaGuillemette Fouquet, Francesca Gay, Eileen Boyle, et al.
European Journal of Haematology|June 25, 2008
Proteomics analysis in post-transplant lymphoproliferative disordersYazan Alsayed, Xavier Leleu, Alexey Leontovich, et al.
Experimental Hematology|December 2, 2009
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patientsKlaudia Kuranda, Céline Berthon, Caroline Dupont, et al.
Expert Review of Hematology|October 1, 2014
Pomalidomide for multiple myelomaGuillemette Fouquet, Claire Bories, Stéphanie Guidez, et al.
Haematologica|September 5, 2008
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myelomaPhilippe Moreau, Valerie Coiteux, Cyrille Hulin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemiaXavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
European Journal of Haematology|May 9, 2024
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA studyMurielle Roussel, Nathalie Texier, Virginie Nael, et al.
Pageof 38

Showing results (41-50 of 372) with videos related to

Sort By:
Pageof 38
Leukemia & Lymphoma|August 10, 2017
Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitorsEmilie Cayssials, Florence Tartarin, Joëlle Guilhot, et al.
Leukemia Research|April 28, 2009
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemiaStéphanie Poulain, Marjan Ertault, Xavier Leleu, et al.
Cancer Immunology, Immunotherapy : CII|September 4, 2010
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitorsCéline Berthon, Virginie Driss, Jizhong Liu, et al.
Cancer Treatment and Research|October 4, 2016
Treatment of Newly Diagnosed Elderly Multiple MyelomaGuillemette Fouquet, Francesca Gay, Eileen Boyle, et al.
European Journal of Haematology|June 25, 2008
Proteomics analysis in post-transplant lymphoproliferative disordersYazan Alsayed, Xavier Leleu, Alexey Leontovich, et al.
Experimental Hematology|December 2, 2009
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patientsKlaudia Kuranda, Céline Berthon, Caroline Dupont, et al.
Expert Review of Hematology|October 1, 2014
Pomalidomide for multiple myelomaGuillemette Fouquet, Claire Bories, Stéphanie Guidez, et al.
Haematologica|September 5, 2008
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myelomaPhilippe Moreau, Valerie Coiteux, Cyrille Hulin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemiaXavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
European Journal of Haematology|May 9, 2024
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA studyMurielle Roussel, Nathalie Texier, Virginie Nael, et al.
Pageof 38